Analgesic effects of the somatostatin sst4 receptor selective agonist J-2156 in acute and chronic pain models.
Eur J Pharmacol, 2006/6/06;539(1-2):71-5.
Sándor K[1], Elekes K, Szabó A, Pintér E, Engström M, Wurster S, Szolcsányi J, Helyes Z
Affiliations
PMID: 16697366
Impact factor: 5.195
Abstract
Somatostatin released from capsaicin-sensitive afferents exerts systemic anti-nociceptive actions, presumably via somatostatin receptor subtype 4 (sst4). In the present study, the antinociceptive effects of a novel somatostatin sst4 receptor selective peptidomimetic compound, J-2156 (1-100 microg/kg i.p.), were examined. J-2156 inhibited nocifensive behaviour of mice in the second phase of the formalin test. Adjuvant-evoked chronic inflammatory mechanical allodynia was decreased in rats treated with J-2156 for 21 days. Sciatic nerve ligation-induced neuropathic mechanical hyperalgesia was inhibited by J-2156 on the seventh postoperative day. Results obtained using this highly selective agonist suggest that somatostatin sst4 receptors represent a promising target for new perspectives in analgesic therapy.
MeSH terms
Acute Disease; Analgesics; Animals; Butanes; Chronic Disease; Hyperalgesia; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Naphthalenes; Pain; Pain Measurement; Pain Threshold; Physical Stimulation; Rats; Rats, Wistar; Receptors, Somatostatin; Sulfones; Touch
More resources
EndNote: Download